Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

30 janv. 2018 16h47 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Clinical Hold on BPX-501 Clinical Trials in the United States

HOUSTON, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
11 déc. 2017 10h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Announces Presentations of its Controllable Switch Technology Platform at the American Society of Hematology 2017 Annual Meeting

ATLANTA, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
09 déc. 2017 14h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Data Presentation Demonstrating Improved Immune Recovery Following Haploidentical Stem Cell Transplant with BPX-501 in Children with Blood Cancers and Nonmalignant Diseases

ATLANTA, Dec. 09, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
08 nov. 2017 07h00 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals to Present at the Jefferies 2017 London Healthcare Conference

HOUSTON, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
07 nov. 2017 16h05 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Third Quarter 2017 Financial Results

HOUSTON, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
01 nov. 2017 09h17 HE | Source: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Data Presentations on Lead Product Candidate BPX-501 and CAR-T Program at the 59th American Society of Hematology Annual Meeting

HOUSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
30 août 2017 07h00 HE | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals to Present at Three Healthcare Investor Conferences in September

HOUSTON, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
08 août 2017 16h05 HE | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update

Company updates BPX-501 program Enrollment progressing in early clinical trials of CAR T and TCR product candidates Company to host conference call and webcast on August 8 at 5:00 PM EDT HOUSTON,...
03 août 2017 07h00 HE | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals Appoints Gregory Naeve as Chief Business Officer

HOUSTON, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
01 août 2017 07h00 HE | Source: Bellicum Pharmaceuticals

Bellicum Pharmaceuticals to Report Second Quarter 2017 Financial Results and Host Conference Call and Webcast on August 8, 2017

HOUSTON, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...

Page précédente

Page suivante